BioSante Pharmaceuticals to Ring NASDAQ Closing Bell
Lincolnshire, Illinois (January 15, 2008) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Dr. Louis W. Sullivan, its chairman, and Stephen M. Simes, its chief executive officer, will ring the closing bell at the NASDAQ site in Times Square on Thursday January 17, 2008. The bell ringing is in honor of BioSante’s recent move of its listing to the NASDAQ Stock Market.
“Closing the NASDAQ is a tremendous honor and an opportunity to commemorate our new NASDAQ listing,” said Simes, of the event.
In addition, BioSante announced that Mr. Simes, will present a corporate update and overview at the Flaherty Financial/Wall Street Research Small Cap Conference, in New York City. Mr. Simes will present on January 22, 2008 at 12:00 p.m. local time. The Flaherty Conference will feature companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors.
A live audio webcast of BioSante’s presentation at the Flaherty Conference may be accessed at biosantepharma.cdmail.biz and a replay will be available at the same link for 60 days.
NASDAQ® is the largest U.S. electronic stock market. With approximately 3,100 companies, it lists more companies and, on average, its systems trade more shares per day than any other U.S. market. NASDAQ is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ website at http://www.nasdaq.com or the NASDAQ NewsroomSM at http://www.nasdaq.com/newsroom
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD) and Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante’s licensee.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.